Keel Pharmaceuticals

Keel Pharmaceuticals is a private biotechnology company focused on the discovery and development of novel small molecule therapeutics, primarily for oncology. Headquartered in Edmonton, Canada, the company was established by Christopher Micetich, the founder of Fedora Pharmaceuticals, which is notable for its major licensing agreement with Roche. Keel Pharmaceuticals utilizes a proprietary medicinal chemistry platform and a vast library of chemical compounds to identify and optimize drug candidates for challenging biological targets. The company's approach combines structural biology with advanced synthesis to create high-affinity molecules with the potential to address significant unmet needs in cancer treatment. Currently in the pre-clinical stage, Keel Pharmaceuticals continues to advance its internal pipeline while leveraging the deep drug discovery expertise of its leadership team.